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Abstract
Insulin resistance progressing to type 2 diabetes mellitus (T2DM) is marked by a broad perturbation of macronutrient
intermediary metabolism. Understanding the biochemical networks that underlie metabolic homeostasis and how they
associate with insulin action will help unravel diabetes etiology and should foster discovery of new biomarkers of disease
risk and severity. We examined differences in plasma concentrations of .350 metabolites in fasted obese T2DM vs. obese
non-diabetic African-American women, and utilized principal components analysis to identify 158 metabolite components
that strongly correlated with fasting HbA1c over a broad range of the latter (r=20.631; p,0.0001). In addition to many
unidentified small molecules, specific metabolites that were increased significantly in T2DM subjects included certain amino
acids and their derivatives (i.e., leucine, 2-ketoisocaproate, valine, cystine, histidine), 2-hydroxybutanoate, long-chain fatty
acids, and carbohydrate derivatives. Leucine and valine concentrations rose with increasing HbA1c, and significantly
correlated with plasma acetylcarnitine concentrations. It is hypothesized that this reflects a close link between abnormalities
in glucose homeostasis, amino acid catabolism, and efficiency of fuel combustion in the tricarboxylic acid (TCA) cycle. It is
speculated that a mechanism for potential TCA cycle inefficiency concurrent with insulin resistance is ‘‘anaplerotic stress’’
emanating from reduced amino acid-derived carbon flux to TCA cycle intermediates, which if coupled to perturbation in
cataplerosis would lead to net reduction in TCA cycle capacity relative to fuel delivery.
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Introduction
Type 2 diabetes mellitus (T2DM) is a progressive disease in
which increasingly poor insulin sensitivity and hyperinsulinemia
precede, typically for several years, the onset of frank diabetes [1].
The central feature of the insulin resistance involves reduced
insulin-mediated glucose uptake and metabolism, particularly in
skeletal muscle. However, evidence also suggests dysregulated fatty
acid metabolism and tissue lipid accumulation as being associated
with the development of insulin resistance and T2DM [2;3].
Furthermore, in human obesity and in some obese, diabetic
animal models an elevation of circulating branched chain amino
acid (BCAA) concentrations has been reported [4–9]. Thus,
insulin resistance progressing to T2DM is marked by a broad
perturbation of macronutrient intermediary metabolism.
Excessive cellular accumulation of lipids in muscle [10–17], liver
[18], and adipocytes [19] is associated with insulin resistance in
those tissues. Lipotoxicity in pancreatic b-cells also is proposed as a
factor leading to loss of b-cell function in T2DM [20]. In skeletal
muscle specifically, lower long-chain fatty acid (LCFA) oxidation
in the fasted state and a blunted increase of carbohydrate
oxidation in response to increased insulinemia (‘‘metabolic
inflexibility’’) is a common feature of pre-diabetes and T2DM
[21]. Insulin resistance may be accompanied by a greater
mismatch between muscle LCFA delivery and tissue oxidative
capacity, leading to accumulation of by-products of incomplete
LCFA oxidative catabolism [22]. Consistent with this model,
acylcarnitines resulting from incomplete LCFA b-oxidation were
more prevalent and elevated in the plasma of type 2 diabetic
women compared to non-diabetics [23]. However, the tissue
source of these metabolites cannot be pinpointed from plasma
patterns alone. The molecular factors linking inefficient LCFA
catabolism to impaired insulin action remain controversial, but
may include build-up of cytosolic ceramide and diacylglyerol
(DAG) that inhibit Akt/PKB and activate PKC enzymes,
respectively (see reviews by [24–26]). Increased tissue exposure
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associated with insulin resistance via toll like receptors 2 and 4,
and we reported that at least some acylcarnitines elevated in
T2DM plasma can trigger NFkB-driven gene expression,
suggesting that these metabolites have pro-inflammatory proper-
ties as well [23].
Understanding the biochemical networks underlying metabolic
homeostasis and their association with insulin sensitivity will help
to clarify diabetes etiology, and should foster the discovery of new
biomarkers of disease risk and severity. It would be particularly
useful to identify metabolite signatures specific to muscle LCFA
oxidation considering the importance of lipid metabolism in this
tissue to whole-body insulin sensitivity. However, there is a paucity
of comparative experimental models in which b-oxidation is
altered exclusively or predominantly in muscle cells. To address these
problems, we have applied metabolomics platforms to compare
plasma metabolite patterns in weight-matched obese non-diabetic
and T2DM African-American women, with or without an
uncoupling protein 3 (UCP3) g/a missense polymorphism that
results in substantial reductions in whole-body LCFA oxidation
[27]. Considering that UCP3 is essentially muscle-specific in
humans, examination of metabolic patterns in persons harboring
the UCP3 g/a polymorphism holds promise to uncover muscle-
specific moieties reflective of altered muscle b-oxidation. The
archived plasma samples examined herein are identical to those
used in our recent report of acylcarnitine profiles in this cohort
[23], and this complementary work extends the metabolite
coverage to .400. The results indicate that variances in a unique
subset of metabolites successfully discriminate non-diabetics from
T2DM subjects. The metabolite patterns highlight that indices of
poor blood sugar control, and markers of inefficient TCA cycle
function, strongly correlate with increased plasma BCAA concen-
trations, which we propose reflects disruption of normal amino
acid catabolism and hence imbalanced anaplerosis. The data also
point to a potential role of mitochondrial UCP3 in regulation of
glutamate/a-ketoglutarate/butanoyl-CoA metabolism.
Methods
Human Volunteers and Blood Plasma Collection
Comprehensive details regarding the study cohort and sample
collection were previously-described [23]. Briefly, archived plasma
samples derived from body mass index- (BMI) and age-matched
overweight to obese type 2 diabetic (n=44) and non-diabetic
(n=12) Gullah-speaking African-American women with or
without a UCP3 g/a missense polymorphism were evaluated.
Volunteers were recruited as part of the Project SuGAR study
described in detail elsewhere [28–31]. Considering that this group
is of a single sex, displays an extraordinarly low genetic admixture,
lives in a relatively small geographical space, and has a common
dietary intake pattern, we anticipate that the cohort is well-suited
for metabolomics studies since biological metabolite signal-to-noise
should be low. Ethics Statement: Studies were approved by the
Institutional Review Boards of the Medical University of South
Carolina, University of Alabama at Birmingham, and the
University of California, Davis, and all participants provided
written informed consent. Blood was collected by arm venipunc-
ture between ,08:00–09:00 into EDTA-treated collection tubes
after an overnight fast (no food or drink since 20:00 the night
before). Plasma was frozen at 220uC for 1–7 days before transport
to 280uC freezers for longer-term storage. Volunteers were asked
to avoid unusual activity and intentional exercise in the 3 days
leading up to the study, and were instructed to continue to eat
their habitual diet without unusual deviations. Patients with
T2DM did not take doses of oral agents on the evening before and
on the morning of study. Patients treated with insulin could take
regular or rapid acting insulin at dinner the night before the study
but were instructed to withhold any intermediate- or long-acting
insulin on the evening before, and to avoid insulin injections on the
morning of the study.
Metabolite Analysis
Plasma samples for metabolomics assays were thawed on ice,
aliquoted, re-frozen on dry ice, and stored at 280uC prior to
delivery to the Fiehn lab. Plasma aliquots (15 mL) were extracted
and derivatized as reported previously [29] using 1 mL of
degassed acetonitrile:isopropanol:water (3:3:2; v/v/v) at 220uC,
centrifuged and decanted with subsequent evaporation of the
solvent to complete dryness. A clean-up step with 500 mL
acetonitrile/water (1:1; v/v) removed membrane lipids and
triglycerides and the supernatant was dried down again. A set of
13 C8–C30 fatty acid methyl ester internal standards were added
and samples were derivatized by 10 mL methoxyamine hydro-
chloride in pyridine followed by 90 ml MSTFA (1 mL bottles,
Sigma-Aldrich) for trimethylsilylation of acidic protons. A Gerstel
MPS2 automatic liner exhange system (Mu ¨lheim an der Ruhr,
Germany) was used to inject 0.5 mL of sample at 50uC (ramped by
to 250uC) in splitless mode with 25 s splitless time. Analytes were
separated using an Agilent 6890 gas chromatograph (Santa Clara,
CA) equipped with a 30 m long, 0.25 mm i.d. Rtx5Sil-MS column
with 0.25 mm 5% diphenyl film and additional 10 m integrated
guard column (Restek, Bellefonte PA). Chromatography was
performed with constant flow of 1 mL/min while ramping the
oven temperature from 50uC for to 330uC with 22 min total run
time. Mass spectrometry was done by a Leco Pegasus IV time of
flight mass spectrometer (St. Joseph, MI) with 280uC transfer line
temperature, electron ionization at 270eV and an ion source
temperature of 250uC. Mass spectra were acquired from m/z 85–
500 at 17 spectra s
21 and 1850 V detector voltage. Result files
were exported to our servers and further processed by our
metabolomics BinBase database [32]. All database entries in
BinBase were matched against the Fiehn mass spectral library of
1,200 authentic metabolite spectra using retention index and mass
spectrum information or the NIST05 commercial library.
Identified metabolites were reported if present within at least
50% of the samples per study design group (as defined in the
SetupX database) [33]. Peak heights of quantifier ions defined for
each metabolite in BinBase were normalized to the sum intensities
of all known metabolites and used for statistical investigation.
External 5-point calibration curves established with quality control
mixtures containing 30 metabolites controlled for instrument
sensitivity. Each chromatogram was further controlled with
respect to the total number of identified metabolites and total
peak intensities to ensure that outliers did not confound the
subsequent statistical analysis.
Statistical Analyses
A mixture of univariate and multivariate statistics were applied
to the investigation of changes in this study. Differences in mean
plasma analyte concentrations between subjects with different
UCP3 genotypes or diabetic status were initially evaluated using
unpaired Student’s t-tests with multiple comparison adjustments
made using the method of Benjamini and Hochberg [34]. A false
discovery rate (FDR) of 20% (i.e., q=0.2) was applied. Principal
components analyses (PCA) were used to independently assess
metabolites that segregated with genotype and diabetic status.
Specifically, all detected metabolites were used as input variables,
and principal components were ranked on significant differences
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using the Microsoft Excel add-in developed by the Bristol Centre
for Chemometrics, University of Bristol, UK (http://www.chm.
bris.ac.uk/org/chemometrics/chemometrics.html). The Pearson’s
correlation statistic was used to determine relationships between
select metabolites (PrismGraph, GraphPad, San Diego, CA). All
results are presented as means 6 SEM, and P,0.05 was
considered statistically significant.
Results
Over 700 discrete signals were detected using GC-TOF mass
spectrometry for each plasma sample. After applying the BinBase
database filtering, 366 metabolites passed stringent analytical
quality control measures, and used for comparisons of diabetic vs.
non-diabetic and UCP3 g/g vs. UCP3 g/a plasma metabolomic
profiling. The identities of these metabolites are provided in
Table S1 (genotype comparisons) and Table S2 (diabetes
comparisons). Metabolites lacking full structural identification
(‘‘unknowns’’) are unambiguously described by BinBase (BB)
numbers and full mass spectra, quantifier ions and retention
indices. These data are publically available and queryable against
all 24,000 samples in BinBase (http:\\eros.fiehnlab.ucdavis.
edu:8080/binbase-compound/).
Plasma Metabolite Profiles in Non-Diabetic UCP3 g/g and
g/a Polymorphs
In non-diabetic persons harboring the missense g/a UCP3
allele, although there were 35 metabolites with mean plasma
concentrations at least 50% higher vs. g/g subjects (Table S1), the
difference in only 2 metabolites achieved statistical significance
assessed by unpaired two-tailed t-tests (BB226860 and BB219174;
Table 1). In contrast, 14 of 18 plasma metabolites reduced by at
least 50% in g/a polymorphs were significantly different compared
to g/g subjects (Table 1). However, changes did not achieve
statistical significance after applying a 20% FDR correction (see
Methods). Regardless, it is notable that concentrations of 2-
oxoglutarate (a-ketoglutarate) and glutamate were both reduced in
non-diabetic subjects harboring the g/a allele. In addition, our
previous report of a 36% reduction in plasma lactate concentra-
tion in non-diabetic g/a subjects measured by standard clinical
chemistry analyses [23] was confirmed by mass spectral analysis
(Table S1). Most metabolites that were significantly altered in
non-diabetic g/a individuals vs. g/g individuals remain uniden-
tified (Table 1 and Table S1).
Plasma Metabolite Comparisons in Non-Diabetic and
Type 2 Diabetic Subjects
As expected, comprehensive metabolomics analysis of diabetic
vs. non-diabetic plasma revealed significantly increased concen-
trations of glucose, long-chain fatty acids (LCFAs: oleic, palmito-
leic, palmitic), and the ketone body 3-hydroxybutanoic acid (b-
hydroxybutyrate) in T2DM subjects (Table 2). The mean plasma
concentrations of 36 metabolites increased $50% in T2DM
subjects vs. non-diabetics (Table S2). A total of 59 plasma
metabolites were decreased in T2DM subjects: 18 metabolites
were reduced by at least 25% in diabetics vs. non-diabetics, and 1
of these had a concentration .50% lower in T2DM (BB281134;
Table S2). All metabolites that were significantly different when
comparing diabetic vs. non-diabetic subjects passed the 20% FDR
threshold. Most metabolites altered in diabetics remain unidenti-
fied in terms of chemical nomenclature; known metabolites are
listed in Table 2.
Of the metabolites that differed in T2DM subjects, it was notable
that plasma leucine concentration was significantly increased by
,50% (Table 2), and its initial catabolic metabolite, 2-ketoisoca-
proic acid (a-ketoisocaproate), was significantly increased by ,27%
(Table 2). Mean plasma valine concentration was ,20% higher in
type 2 diabetic subjects vs. non-diabetics (Table S2), but this
difference was not statistically significant. When leucine and valine
were each considered in terms of their enrichment in the total
plasma amino acid pool (expressed as a % of the total summed
quantifierionpeakheights ofalldetected amino acids),thediabetes-
related increases in these BCAAs were even more apparent and
statistically significant for both leucine % and valine % (Figure 1).
Leucine % enrichment increased concurrent with worsening blood
sugar control since degree of enrichment correlated significantly
with hemoglobin A1c (HbA1c%)(Figure 2A). The relationship
between valine % and HbA1c was less robust (Figure 2B).
Using results from our previous study of plasma acylcarnitine
patterns in these same samples [23], both leucine and valine %
enrichment in the plasma amino acid pool were found to correlate
strongly (p,0.001) with acetylcarnitine concentration (Figure 2C
and 2D). It can also be seen that increasing valine % enrichment
is coincident with a reduction in relative concentrations of
propionylcarnitine, a marker of the valine catabolic product
propionyl-CoA; these patterns are associated with increasing
acetylcarnitine concentrations (Figure 3).
To identify the specific plasma metabolites with distributions
most affectedbysubjects’diabetesstatus,wefirstemployedPCA,an
unsupervised multivariate analysis approach, and considered four
principal components (PC) dimensions. Metabolite variation in PC
dimensions 2 and 3 (PC2, PC3) explained 16.8% of the variance
between groups, and the differences between diabetic vs. non-
diabetic PC scores were highly significant (P,0.001 for both PC2
and PC3)(data not shown). A principal components (metabolites)
selection criterion for diabetic and non-diabetic group discrimina-
tion was set for components with loadings (i.e., variance
contribution) $1 standard deviation from the mean loading value
in each of the discriminating PC2 and PC3 dimensions. The 158
metabolite components emerging from this approach were used in a
secondaryPCAto further refinetheprincipal componentsthat most
accurately predict the type 2 diabetic phenotype (this analysis did
not include glucose since this metabolite defines diabetes status). In
this secondary PCA, PC1explained40% of the group variance, and
the mean PC1 scores in diabetics and non-diabetics were
significantly different (p,0.0001), indicating successful phenotype
discrimination. An additional 18.3% of the total group variance was
accounted for in the PC2 dimension, and the mean PC2 scores in
diabetics and non diabetics were significantly different (p,0.0001).
The PC1 and PC2 scores were thus plotted for each of the diabetic
andnon-diabeticsubjectstovisualizethe magnitudeofseparationof
the groups (Figure 4): excellent separation of diabetic and non-
diabetic subject cohorts was achieved. Loadings for each of the
discriminating factors may be found in Table S3; metabolites with
loadings at the highest and lowest extremes in PC1 and PC2 are
those with variances most strongly impacting the phenotype
separation in the PC1 and PC2 dimensions in Figure 4. The PC1
scores derived from the selected metabolites were highly correlated
with the degree of blood sugar control (blood HbA1c%), indicating
a significant association between person-to-person differences in
these metabolites and the diabetic phenotype (Figure 5).
Discussion
Type 2 diabetes mellitus is a disease of abnormal intermediary
metabolism of an array of nutrients including glucose. For
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highlighted in the seminal studies by Randle et al. indicating that
muscle glucose utilization can be inhibited by increased provision
of long chain fatty acids (LCFAs)[35]. Later perspectives from
McGarry, Kelly and others pointed out that abnormal fatty acid
oxidation and ectopic tissue lipid accumulation are at the core of
insulin resistance and T2DM genesis (see [2;21]), and Unger et al.
have implicated lipotoxicity in pancreatic b-cell dysfunction
[3;20]. There is now strong evidence that incomplete or inefficient
LCFA b-oxidation accompanies insulin resistance and T2DM
[22;23]. The underlying mechanisms for this association remain
controversial, but it appears that sub-optimal whole-tissue
tricarboxylic acid (TCA) cycle function in some tissues contributes
to the metabolic phenotype in the insulin-resistant state [36–40].
Thus, to fully understand the metabolic landscape of T2DM, it is
necessary to comprehensively determine how multiple pathways
change in this condition and to evaluate how disparate pathways
interconnect. Efforts to identify specific metabolites associated with
T2DM and insulin resistance hold promise in developing clinically
facile, predictive diagnostic and prognostic toolsets to predict
diabetes risk, to determine disease stage, elucidate causal
mechanisms, and to evaluate the efficacy of modalities aiming to
thwart T2DM.
We have taken advantage of advancements in analytical
chemistry and informatics tools to determine diabetes-associated
patterns of .350 plasma metabolites encompassing carbohydrate,
lipid, amino acid, purine, and organic acid classes. These results
complement and extend our previous results regarding plasma
acylcarnitines in the same subjects [23]. Marked differences in the
plasma metabolome of diabetic and non-diabetic obese African-
American women were observed, and identified a set of specific
metabolites whose variability was strongly correlated with HbA1c,
an index of long-term blood sugar control. These metabolites,
therefore, appear to be good candidate biomarkers of blood sugar
control and may provide insights into metabolic disease etiology.
In at least some cases, differentially-abundant plasma metabolites
appear to have resulted from hyperglycemia and increased flux of
excess glucose toward secondary conversion pathways: i.e.,
increased fasting plasma fructose concentrations in T2DM subjects
indicative of fructose generation (Table 2; also see [41]), and
elevated glucuronic acid and xylose (Table 2). The concentrations
of less than 10% of the measured metabolites in the current study
displayed significant differences of 2-fold or greater when
comparing T2DM vs. non-diabetic subjects, and these metabolites
might be some of the strongest biomarkers of metabolic health
status. Additional potential candidate diabetes biomarkers
emerged from PCA analysis, including 93 metabolites for which
variance-derived loading values were .1 standard deviation from
the mean (Table S3) indicating their strong influence on PC
scores that separated diabetics from non-diabetics (Figure 4). The
PCA metabolite loading value patterns (Table S3) revealed that
many metabolites reflecting the diabetic phenotype discovered
here await identification since their retention times and m/z ratios
did not match standards available to the investigators at the time
of analysis. Furthermore, metabolite loading values in both PC1
and PC2 indicated that separation of diabetic and non-diabetic
metabolic phenotypes involved variation in several chemical
classes, viz. select carbohydrate derivatives (i.e., fructose, glucuro-
Table 1. Plasma metabolites with significantly-altered concentrations in non-diabetic obese African-American women harboring a
UCP3 g/a missense allele.
g/g genotype (n=6) g/a genotype (n=6)
Relevant Metabolic
Pathway
g/a to g/g
Ratio
Increased in non-diabetic g/a:
BB226860 25526669 585161302 unknown 2.29*
BB219174 69666988 1025361074 unknown 1.47*
Decreased in non-diabetic g/a:
BB223521 35696340 25166318 unknown 0.71*
phosphoric acid 15407256106083 1065028688171 acid/base balance? 0.69**
BB223506 48846343 32886483 unknown 0.67*
BB281189 432579645901 285112614032 unknown 0.66**
inulobiose 12236152 795687 carbohydrate 0.65*
BB228147 579667 374649 unknown 0.65*
BB211382 3648463617 2165163493 unknown 0.59**
cysteine 2451964380 1382761928 amino acid 0.56*
2-oxoglutarate (a-ketoglutarate) 22096240 11826130 TCA cycle/transamination 0.54**
BB281112 1834262886 918962265 unknown 0.50*
BB228144 38746659 19106524 unknown 0.49*
BB239966 23586418 11586308 unknown 0.49*
glutamic acid (glutamate) 4814667473 2104861427 amino acid 0.44**
BB222169 2552664397 1074364133 unknown 0.42*
Values are quantifier peak height means 6 SEM; see Supplemental Table S1 for full list of metabolites including those whose concentration differences were not
statistically significant;
*p#0.05;
**p#0.01 (unpaired t-test).
Note that after application of a 20% false discovery rate (see Methods) these differences did not achieve statistical significance.
doi:10.1371/journal.pone.0015234.t001
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patterns in both PC dimensions (see Figure 4 legend). This
indicates a concurrent impact of diabetes on intermediary
metabolism of all classes of macronutrients.
Several recent investigations of urine and blood metabolomics
patterns associated with T2DM or insulin resistance have provided
insights into pathways influenced by these conditions (i.e.,
[8;23;42–46]). One common finding comparing our results to
those of others [42;43;46] is a higher concentration of 2-
hydroxybutanoic acid (2-HB; a-hydroxybutryrate) in T2DM
biofluids. Plasma concentrations of 2-HB were reported to be
negatively correlated with insulin sensitivity [46], and our results
are consistent with this observation in that plasma 2-HB
concentrations were positively correlated with HbA1c in our
cohort (r=0.455, P=0.001). Gall et al. speculated that increased
2-HB results from higher conversion of amino acid-derived 2-
ketobutanoic acid (2-KB; a-ketobutyrate) to 2-HB via lactate
dehydrogenase, in conjunction with increases in the tissue
NADH/NAD+ ratio concurrent with reduced insulin sensitivity
and increased LCFA catabolism. Since the 2-HB precursor 2-KB
is a product of cystothionine gamma-ligase activity that produces
2-KB plus cysteine, higher plasma concentrations of cysteine and
its related metabolite cystine in insulin-resistant states (Table S2;
also see [46;47]) support the idea that flux through the
methionine/cystathionine catabolic pathway is altered with
increasing insulin resistance.
Further supporting that insulin resistance and T2DM are
conditions associated with abnormal amino acid metabolism,
elevated blood concentrations of BCAAs have been consistently
observed in rodent models of obesity [5–9;48] and in obese and/or
Table 2. Identifiable plasma metabolites with significantly-altered concentrations in obese non-diabetic vs. type 2 diabetic
African-American women.
Non-Diabetic
(n=12)
Diabetic
(n=43) Relevant Metabolic Pathway
Diabetic/Non-
Diabetic Ratio
Increased in Diabetes:
3-hydroxybutanoic acid (b-hydroxybutryrate) 1067661455 4742469450 lipid/fatty acid 4.44*
oleic acid 883761105 2337762189 lipid/fatty acid 2.65***
gluconic acid 25706230 53176229 carbohydrate 2.07****
fructose 255053634001 517922618549 carbohydrate 2.03****
palmitoleic acid 628661444 1140061018 lipid/fatty acid 1.81*
3,6-anhydrogalactose 16606147 29206116 carbohydrate (microbial?) 1.76****
glucuronic acid 17186151 28446264 carbohydrate 1.66*
glucose 1057532690953 1644213656650 carbohydrate 1.56****
heptadecanoic acid 116306554 1791161564 lipid/fatty acid 1.54*
inulobiose 10096106 1546692 carbohydrate 1.53**
leucine 110271614147 16428169806 amino acid 1.49**
2-hydroxybutanoic acid (a-hydroxybutryrate) 100560621376 14685369844 amino acid 1.46*
2-deoxyerythritol 82706727 109506383 lipid/fatty alcohol 1.32**
palmitic acid 7518565308 9829466003 lipid/fatty acid 1.31*
2-ketoisocaproic acid (a-ketoisocaproate) 48096462 61696309 amino acid 1.28*
uridine 850651 1085651 pyrimidine 1.28*
cystine 3053463583 3849661818 amino acid 1.26*
xylose 43886290 54796221 carbohydrate/pentose phosphate 1.25*
histidine 4496962332 5607162178 amino acid 1.25**
stearic acid 598153631201 719217624664 lipid/fatty acid 1.20*
Decreased in Diabetes:
benzylalcohol 1776261062 157416405 phenolic metabolite or xylene
(microbial?)
0.89*
benzoic acid 3784162445 3296861066 phenolic metabolite or xylene
(microbial?)
0.88*
lysine 170439613635 14162666008 amino acid 0.83*
ethanolamine 479789642252 380214619511 choline precursor 0.79*
arachidonic acid 3512363669 2605861410 lipid/fatty acid 0.74**
glycine 326074641720 239650616035 amino acid 0.74*
glycerol-3-phosphate (glycerol-a-phosphate) 2392062430 1657161018 glycerophospholipid 0.69**
Values are quantifier peak height means 6 SEM; see Supplemental Table S2 for information on unknown metabolites significantly changed in T2DM;
*p#0.05;
**p#0.01;
***p#0.001;
****p#0.0001 (unpaired t-test).
doi:10.1371/journal.pone.0015234.t002
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PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15234Figure 1. Relative plasma concentrations of leucine (A) and valine (B) are increased in type 2 diabetic African-American obese
women. Results are expressed as total quantifier peak height percent of all summed plasma amino acid (AA) peak heights, i.e., as % of total AA. Bars
represent the mean 6 SEM for n=12 and n=43 non-diabetic and diabetic subjects, respectively. **p,0.01, unpaired t-test. Absolute quantifier peak
heights are presented in the Results.
doi:10.1371/journal.pone.0015234.g001
Figure 2. Plasma branched chain amino acid (BCAA) concentrations are correlated with fasting HbA1c% and plasma acylcarnitine
concentrations in non-obese (yellow circles) and type 2 diabetic (blue circles) obese women. Shown are correlations between plasma
leucine (A,C) and valine (B,D) enrichments (% of their concentrations relative to total measured amino acid concentrations; see Figure 1 legend) with
fasting blood HbA1c (top panels) or plasma acetylcarnitine concentration (bottom panels). Pearson’s r and p values for the correlations are given
within the figures.
doi:10.1371/journal.pone.0015234.g002
Metabolite Signature of Type 2 Diabetes
PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e15234T2DM human subjects (i.e., [8,49]. In line with these findings,
plasma leucine, 2-ketoisocaproic acid, and valine concentrations
and/or their relative abundance in the total AA pool were
increased in obese type 2 diabetic vs. obese non-diabetic African-
American women in the current study (Figure 2). It has been
asserted that higher concentrations of BCAA in obesity cause or
exacerbate insulin resistance through mechanisms involving
activation of the molecular target of rapamycin (mTOR)[8].
However, this model remains controversial. First, it is not clear
that the magnitude of increase in fasting blood BCAA in obesity or
T2DM are of high enough magnitude to trigger mTOR to a level
that would negatively impact insulin action in situ. Second, BCAA-
rich dairy-based diets have consistently been shown to have anti-
obesity properties in rodent models (see [50]). Third, leucine
supplementation to diet-induced obese mice either had no effect
[51] or substantially improved [52] metabolic profiles. Finally,
protein-rich diets often have positive metabolic effects in type 2
diabetic and obese humans (see [53;54]).
Thus, we favor the idea that higher fasting blood BCAA (and
some other AA) in insulin-resistant states results simply marks
reduced catabolism in key tissues, and this reduced catabolism is
hypothesized to limit tissue concentrations of AA derivatives
important to normal metabolism. Supporting this perspective are
reports indicating that the two initial catabolic enzymes of BCAA
catabolism, mitochondrial branched-chain amino acid amino-
transferase (BCATm) and branched-chain a-ketoacid dehydroge-
nase (BCKD) expression and specific activities are reduced in the
liver and/or white adipose tissue (WAT) of obese rodents
[6;7;9;48]. She et al. [6] demonstrated that obese human subjects
who underwent bariatric surgery had significantly reduced plasma
BCAA concentration .1 yr post-surgery concurrent with in-
creased WAT BCKD and BCATm activities. Whole-body BCAA
clearance was reportedly ,20% reduced in T2DM subjects [4]
and recently an insulin resistance effect on leucine protein
fractional synthesis rate was demonstrated [55;56]. However,
other reports have indicated that leucine oxidation or amino acid
turnover is not impaired in obese or type 2 diabetic persons [57–
63]. Clearly, additional research is needed to identify tissue-
specific alterations in the fates of protein and amino acids in
obesity and diabetes to better understand the basis for elevations in
blood concentrations of BCAA and certain other amino acids
under these conditions. Interestingly, higher circulating concen-
trations of 2-HB are associated with perturbation in biotin
metabolism, specifically in inherited biotinidase deficiencies [64],
and poor biotin status has been associated with insulin resistant
Figure 3. Relative plasma concentrations of propionylcarnitine
(green symbols) were reduced concurrent with increases in the
relative plasma concentrations of a precursor, valine, with
increasing plasma acetylcarnitine concentration in obese
African-American women. Symbols represent individuals included
in metabolomics studies described in the text.
doi:10.1371/journal.pone.0015234.g003
Figure 4. Separation of non-diabetics (yellow circles) from type 2 diabetics (blue circles) due to variance in plasma metabolite
factors. Principal components analysis (PCA) in dimensions 1 and 2 using 158 metabolites illustrates differential distribution of diabetic and non-
diabetic subjects along the PC1 (X axis) and PC2 (Y axis) axes, with each symbol plotting PC1-PC2 scores for a given subject. Metabolite components
whose variance-derived loadings values contributed most to the PC separations scores are listed in Supplemental Table S3. Summarizing the loading
contributions from known compounds, elevated fatty acids and the enrichment of the amino acid pool with branched chain AAs segregated
diabetics from controls in PC1, while elevations In various carbohydrates as well as a suite of amino acids separated diabetics from controls in PC2.
doi:10.1371/journal.pone.0015234.g004
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activities of carboxylation enzymes involved in BCAA and cysteine
catabolism and TCA cycle anaplerosis (i.e., propionyl-CoA
carboxylase, methylcrotonyl-CoA carboxylase, pyruvate carboxyl-
ase). Thus, while speculative at this time, it is intriguing to consider
that the observed higher plasma 2-HB concentrations with
increasing insulin resistance marks dysfunctional biotin tissue
bioactivity that would in theory impact BCAA and cysteine/
cystine metabolism.
Mitochondrial dysfunction is critical in driving the diabetic
phenotype. Most investigations found a reduced number or
attenuated in vivo activity of muscle mitochondria in insulin
resistant subjects [39;66;67][36–38], but others have reported that
the function of isolated muscle mitochondria is normal in T2DM
[68;69]. This raises the possibility that factors limiting mitochon-
drial activity in diabetics in situ are lost in studies in isolated
organelles. A notable difference is that anaplerotic carbon sources
such as malate, that act to replenish TCA cycle intermediate
(TCAi) carbon loss due to cataplerosis (i.e., loss of TCAi carbon
via export of a-ketoglutarate or its conversion to glutamate) are
invariably included in isolated mitochondrial preparations to
maintain function. In a previous paper using samples from the
current cohort of subjects, we observed that increased plasma
concentrations of acylcarnitine and medium- and long-chain fatty
acylcarnitines were coupled to reductions in propionylcarnitine
concentrations in T2DM. These findings are consistent with a
working model of limited tissue TCA cycle capacity relative to
mitochondrial fuel delivery, due in part to sub-optimal anaplerosis
pathways that replenish TCAi carbon losses from cataplerosis in
vivo [23]. This ‘‘anaplerotic stress’’ model of T2DM, and the
associated concept of anaplerosis/cataplerosis balance in diabetes
[70] remain to be rigorously tested. There is evidence for reduced
tissue concentrations of TCAi in rodent obesity and diabetes
models [22]. While it is not certain if blood or urine patterns of
TCAi reflect intramitochondrial patterns, in T2DM humans
urinary a-ketoglutarate levels were reduced [42] and decreased
urinary phenylacetyl-glutamine–a metabolite in equilibrium with
glutamate and a-ketoglutarate–has been reported in T2DM [45].
It is tempting to consider that dysfunctional BCAA and cysteine
catabolism (see discussion above) contribute to anaplerotic stress
associated with insulin resistance, since valine, isoleucine, and
cysteine are precursors to succinate and succinyl-CoA. Consistent
with this view, plasma valine enrichment in the amino acid pool
rose concurrent with reductions in relative concentrations of
propionylcarnitine (a proxy for a valine anaplerotic product,
propionyl-CoA) as blood sugar control worsened and plasma
acetylcarnitine accumulation became more apparent in our study
cohort (Figure 5). In theory, changes in matrix a-ketoglutarate
concentration (i.e., via conversion to glutamate or export via the a-
ketoglutarate carrier) could impact both TCA cycle function and
BCAA metabolism, since BCATm activity involves a-ketogluta-
rate. Notably, Seifert et al. recently reported that increases in the
rate of LCFA combustion and concurrent incomplete LCFA b-
oxidation are associated with muscle mitochondrial export of a-
ketoglutarate [71], providing a potential connection between
mitochondrial lipid metabolism and control of a-ketoglutarate
export. The idea that anaplerotic stress and anaplerotic/
cataplerotic balance are factors underlying or exacerbating
metabolic dysfunction in T2DM is compelling, but clearly requires
experimental validation.
Our work has been driven in part by a desire to identify muscle-
specific metabolites associated with LCFA b-oxidation, consider-
ing the importance of efficient skeletal muscle LCFA catabolism to
maintenance of insulin sensitivity. An interesting group to study in
this regard are non-diabetic obese African-American persons
harboring a G304A (g/a) missense allele leading to truncated
UCP3, and who have been found to have significantly reduced
whole-body lipid oxidation [27]. This must in large part emanate
from muscle considering the almost exclusive expression of this
mitochondrial carrier in that tissue in humans [72]. Thus,
differences in circulating metabolites when comparing g/g to g/
a individuals may reflect differences in muscle metabolism. In this
study, we found several metabolites that were altered in overnight-
fasted non-diabetic g/a allele carriers (Table 1, Table S1), and
most await identification and to ascertain tissue-specificity of their
production and utilization. Many metabolite differences between
genotypes were statistically significant, but significance was not
detected after application of a 20% false discovery rate. This was
likely due to limited sample sizes, and indicates that additional
comparative studies are warranted using larger cohorts of g/g and
g/a polymorphic subjects to confirm metabolite differences
observed herein. We observed reductions in plasma concentrations
of a-ketoglutarate and glutamate in g/a individuals, as well as
lower cysteine, suggesting that alteration in UCP3 function in
muscle of obese African-American women impacts TCAi
dynamics and amino acid metabolism. Plasma butyrylcarnitine
(C4-carnitine) was previously found to be reduced by 57% in the
same non-diabetic g/a subjects [23]. Plasma butyrylcarnitine
should be reflective of tissue butyryl-CoA concentrations, and
importantly the latter is a common metabolite in the catabolism of
both glutamate and a-ketoglutarate. Thus, we propose from the
aggregate of results that muscle UCP3 activity may somehow play
a role in regulating tissue a-ketoglutarate/glutamate dynamics.
In summary, broad metabolite profiling of non-diabetic vs. type
2 diabetic plasma, in conjunction with our previous acylcarnitine
profiling, indicates that T2DM is a disease that disrupts multiple
intermediary metabolic pathways including amino acid metabo-
lism. Our data support a hypothetical working model in which
attenuated BCAA, and possibly cysteine, catabolism contribute to
increased blood concentrations of these amino acids and their
derivatives in the insulin-resistant state, and we speculate that this
contributes to anaplerotic stress that is associated with incomplete
oxidation of LCFA and accumulation of acylcarnitines in T2DM.
Variation in a subset of metabolites, including 2-HB, discriminated
Figure 5. Correlation between PC1 scores and blood HbA1c%
in non-diabetic (yellow circles) and type 2 diabetic (blue
circles) obese women. PC1 scores derived from PCA analysis (see
text and Figure 4 legend) were used for correlation to a marker of blood
sugar control. Pearson’s r and p values for the correlation is given within
the figure.
doi:10.1371/journal.pone.0015234.g005
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These metabolites therefore are of interest as potential biomarkers
of disease status and glucose homeostasis. Our results also point to,
for the first time, a potential role of mitochondrial UCP3 in
regulation of the glutamate/a-ketoglutarate/butanoyl-CoA tissue
pool.
Supporting Information
Table S1 Plasma Metabolite list comparing UCP3 g/g
and g/a polymorphs in an obese, African-American
cohort of women. Values are quantifier peak heights deter-
mined for each subject used in the analyses, and metabolites are
identified in the leftward column. Mass spec information is
provided in columns B–E, and in some cases, KEGG identifiers
are provided. Unpaired t-tests were used to evaluate non-diabetic
genotype differences, as noted.
(XLS)
Table S2 Plasma Metabolite list comparing type 2
diabetic and non-diabetic obese African-American wom-
en. Values are quantifier peak heights determined for each subject
used in the analyses, and metabolites are identified in the leftward
column. Mass spec information is provided in columns B–E, and
in some cases, KEGG identifiers are provided. Unpaired t-tests
were used to evaluate differences between diabetic and non-
diabetic women, as noted.
(XLS)
Table S3 Loadings values for each of the principal
components (metabolite factors) used to generate sub-
ject PC scores depicted in Figure 4.
(XLS)
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